新型人用狂犬病疫苗研发管线
狂犬病仍在150多个国家流行,99%的人类病例由犬传播,每年约59,000人死亡。本文讨论处于临床和临床前测试阶段的新型狂犬病疫苗,并评估其替代当前疫苗的潜力。
要点
- 狂犬病在150多个国家流行,99%人类病例经犬传播,每年约59,000人死亡。
- 现有疫苗成本高、暴露后方案需多剂次且重症需联用免疫球蛋白,影响可及性。
- 需要更便宜、免疫原性更强的新疫苗,并改进监测与犬狂犬病控制。
核心结论
- 需要更便宜、免疫原性更强的新型狂犬病疫苗,并改进监测和犬狂犬病控制,以降低人类狂犬病死亡数。
研究设计与样本
- 本文讨论处于临床和临床前测试阶段的新型狂犬病疫苗,并评估其替代当前疫苗的潜力。
主要发现
- 狂犬病仍在150多个国家流行,99%的人类病例由犬传播。
- 该病几乎总是致死,但可通过暴露前和/或暴露后接种疫苗预防。
- 疫苗成本高、暴露后方案需多剂次且重症需联用狂犬病免疫球蛋白、缺乏医疗服务可及性和监测不足,导致每年约59,000例人类死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rabies remains endemic in more than 150 countries. In 99% of human cases, rabies virus is transmitted by dogs. The disease, which is nearly always fatal, is preventable by vaccines given either before and/or after exposure to a rabid animal. Numerous factors including the high cost of vaccines, the relative complexity of post-exposure vaccination protocols requiring multiple doses of vaccine, which in cases of severe exposure have to be combined with a rabies immune globulin, lack of access to health care, and insufficient surveillance contribute to the estimated 59,000 human deaths caused by rabies each year. New, less expensive and more immunogenic rabies vaccines are needed together with improved surveillance and dog rabies control to reduce the death toll of human rabies. Here, we discuss new rabies vaccines that are in clinical and pre-clinical testing and evaluate their potential to replace current vaccines.
引用
- Fooks AR, Banyard AC, Ertl HCJ, et al. New human rabies vaccines in the pipeline. Vaccine. 2018. PMID: 30153997. doi:10.1016/j.vaccine.2018.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。